Myelomatosis clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma
open to eligible people ages 18 years and up
A Phase1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma
at UCLA
Last updated: